期刊
NATURE CHEMICAL BIOLOGY
卷 -, 期 -, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41589-023-01391-6
关键词
-
Enolase 1 (ENO1) is a glycolytic enzyme that promotes cancer development through binding to YAP1 mRNA to enhance its translation, thereby activating alternative arachidonic acid metabolism and prostaglandin E-2 accumulation. Aberrant activation of ENO1/YAP1/PLCB1 and decreased HPGD expression in liver cancer samples suggest a potential correlation between ENO1-regulated AA metabolism and cancer development, highlighting the therapeutic potential of aspirin.
Enolase 1 (ENO1) is a glycolytic enzyme that plays essential roles in various pathological activities including cancer development. However, the mechanisms underlying ENO1-contributed tumorigenesis are not well explained. Here, we uncover that ENO1, as an RNA-binding protein, binds to the cytosine-uracil-guanine-rich elements of YAP1 messenger RNA to promote its translation. ENO1 and YAP1 positively regulate alternative arachidonic acid (AA) metabolism by inverse regulation of PLCB1 and HPGD (15-hydroxyprostaglandin dehydrogenase). The YAP1/PLCB1/HPGD axis-mediated activation of AA metabolism and subsequent accumulation of prostaglandin E-2 (PGE(2)) are responsible for ENO1-mediated cancer progression, which can be retarded by aspirin. Finally, aberrant activation of ENO1/YAP1/PLCB1 and decreased HPGD expression in clinical hepatocellular carcinoma samples indicate a potential correlation between ENO1-regulated AA metabolism and cancer development. These findings underline a new function of ENO1 in regulating AA metabolism and tumorigenesis, suggesting a therapeutic potential for aspirin in patients with liver cancer with aberrant expression of ENO1 or YAP1.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据